Funding for Cerebal Palsy Treatments
Assisting those who have received a placebo treatment
Sparo is pleased to have been selected by Maryland-based NeuroCytonix as its CSR partner. The goal of the NeuroCytonix-Sparo collaboration is to raise funds for several compassionate programs following the completion of NeuroCytonix's FDA-controlled, double-blind, randomized placebo clinical trial on children with Cerebral Palsy. The first program is looking at raising financing for the treatment of the children as part of this completed clinical trial, but who unfortunately had the placebo treatment. A second program will be implemented soon for the treatment of military veterans suffering from neurological consequences of blast injury and concussion.